Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Randomized, Double-blind, Placebo-controlled, Single-dose Study of FX-322 Administered by Intratympanic Injection in Adults With Stable Sensorineural Hearing Loss

Trial Profile

A Phase 1/2 Randomized, Double-blind, Placebo-controlled, Single-dose Study of FX-322 Administered by Intratympanic Injection in Adults With Stable Sensorineural Hearing Loss

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 07 Jan 2019

At a glance

  • Drugs FX 322 (Primary)
  • Indications Sensorineural hearing loss
  • Focus Adverse reactions
  • Sponsors Frequency Therapeutics
  • Most Recent Events

    • 07 Jan 2019 According to a Frequency Therapeutics media release, top-line results are expected in the first half of 2019.
    • 01 Oct 2018 Status changed from recruiting to active, no longer recruiting.
    • 08 Aug 2018 Status changed from planning to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top